Mind Medicine (MindMed) Inc. (MMED.NE)
| Previous Close | 13.61 |
| Open | 12.50 |
| Bid | 14.60 x N/A |
| Ask | 14.95 x N/A |
| Day's Range | 11.60 - 15.07 |
| 52 Week Range | 3.30 - 16.40 |
| Volume | |
| Avg. Volume | 72,598 |
| Market Cap | 1.05B |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireMindMed to Present at Upcoming May Medical Conferences
NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
Business WireMindMed to Present at Upcoming April Medical Conferences
NEW YORK, April 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:
Business WireMindMed Announces Voluntary Delisting from Cboe Canada
NEW YORK, April 01, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be liste
